| Drug General Information |
| Drug ID |
D0E5XA
|
| Former ID |
DCL000210
|
| Drug Name |
R763
|
| Indication |
Haematological malignancies [ICD9: 200-209; ICD10:C81-C86]
|
Phase 1 |
[1]
|
|---|
| Therapeutic Class |
Anticancer Agents
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Target and Pathway |
| Target(s) |
Aurora kinase B |
Target Info |
Inhibitor |
[2]
|
|---|
| Aurora kinase A |
Target Info |
Inhibitor |
[2]
|
|
KEGG Pathway
|
Oocyte meiosis
|
|
Pathway Interaction Database
|
Aurora B signaling
|
|
Signaling by Aurora kinases
|
|
Aurora C signaling
|
|
FOXM1 transcription factor network
|
|
Aurora A signalingaurora_b_pathway:Aurora B signaling
|
|
Integrin-linked kinase signaling
|
|
PLK1 signaling events
|
|
Aurora A signaling
|
|
Reactome
|
APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
|
|
Separation of Sister Chromatids
|
|
Resolution of Sister Chromatid Cohesion
|
|
RHO GTPases Activate Formins
|
|
Mitotic PrometaphaseR-HSA-174178:APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
|
|
Regulation of PLK1 Activity at G2/M Transition
|
|
WikiPathways
|
Mitotic Metaphase and Anaphase
|
|
Mitotic Prometaphase
|
|
Regulation of Microtubule Cytoskeleton
|
|
miR-targeted genes in lymphocytes - TarBase
|
|
miR-targeted genes in epithelium - TarBase
|
|
APC/C-mediated degradation of cell cycle proteinsWP437:EGF/EGFR Signaling Pathway
|
|
JAK/STAT
|
|
Gastric Cancer Network 1
|
|
Integrated Breast Cancer Pathway
|
|
APC/C-mediated degradation of cell cycle proteins
|
| References |
| REF 1 | Clinical pipeline report, company report or official report of Rigel. |
|---|
| REF 2 | Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen. J Cancer Res Clin Oncol. 2009 Jul 17. |
|---|
